Skip to main content
. 2022 Apr 19;6(5):712–725. doi: 10.1002/ags3.12573

TABLE 1.

Characteristics of adult DDLT in Japan

Variables n (%) or mean ± SD
Recipient factor
Sex (male) 250 (55.7)
Age, years 46.3 ± 12.3
Primary liver disease
Acute liver failure 112 (24.9)
Cirrhosis (hepatocellular, viral) 103 (22.9)
Cirrhosis (hepatocellular, non‐viral) 57 (12.7)
Cirrhosis (cholestatic, BA) 30 (6.7)
Cirrhosis (cholestatic, non‐BA) 92 (20.5)
Metabolic disease 30 (6.7)
Others 25 (5.6)
Re‐transplantation 76 (16.9)
Ascites: Moderate 218 (48.6)
Encephalopathy: ≥Ⅲ 58 (12.9)
Medical condition: in ICU 126 (28.1)
Dialysis 118 (26.3)
Anti‐hepatitis C antibody positive 86 (19.2)
BMI, kg/m2 23.4 ± 4.5
MELD score 23.1 ± 8.0
Donor factor
Sex (Male) 263 (58.6)
Age, years 44.2 ± 14.3
Hypertension 81 (18.0)
Diabetes mellites 14 (3.1)
BMI, kg/m2 22.7 ± 3.9
Alcohol history 53 (12.2)
Smoking history 198 (45.3)
Anti‐hepatitis B core antibody positive 47 (10.5)
Cause of death
Trauma 84 (18.7)
Cerebrovascular disease 213 (47.4)
Anoxia 149 (33.2)
Others 3 (0.7)
Duration on respirator, days 9.9 ± 8.2
Catecholamine index 5.9 ± 7.6
Sodium, maximum/ last mEq/L 156.4 ± 10.6/ 141.0 ± 9.7
Total bilirubin, maximum/ last, mg/dL 1.9 ± 2.0/ 1.4 ± 1.7
AST, maximum/ last, IU/L 327 ± 653/ 63 ± 118
ALT, maximum/ last, IU/L 229 ± 517/ 58 ± 82
GGT, maximum/ last, IU/L 134 ± 134/ 97 ± 101
Creatinine, last, mg/dL 1.3 ± 1.6
Image findings of steatosis 45 (10.0)
Pathological findings
Fibrosis (F0‒1/ F2/ not examined) 250/6/193
Steatosis (<30%/ ≥30%/ not examined) 246/12/191
Number of declines for donor reason ≥3 40 (8.9)
Surgical factor
Split liver transplantation 37 (8.2)
Simultaneous liver and kidney transplantation 19 (4.2)
Total ischemic time, h 8.9 ± 2.5

Data were presented as mean values ± SD and numbers (%) for continuous and categorical variables, respectively. B

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BA, biliary atresia; BMI, body mass index; DDLT, deceased‐donor liver transplantation; GGT, gamma‐glutamyl transpeptidase; ICU, intensive care unit; MELD, Model for End‐stage Liver Disease; SD, standard deviations.